FDA approval for capivasertib: and our new collaboration opportunities for industry partners 17 Nov 2023 The US Food and Drug Administration (FDA) has approved the AKT inhibiting drug capivasertib, now given the brand name Truqap, as a breast cancer treatment. Henry French introduces other current opportunities for industry partners to work with ICR researchers, including in the discovery and development of cancer drugs, and asks – could any become the next capivasertib? Find out more Show/Hide